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Version History 
 
Version Release Date Summary of Revisions 
1.0 March 2009 First version publicly released. 
1.1 June 2010 Revised background and text in main body of document. 
Revised case definition criterion based on WG recommendations, pilot responses, 
and CDC recommendations.  
Updated FNHTR definition to allow reaction without documented fever. 
Defined hypotension for infants and small children 
Clarified TAGVHD probable and possible criteria. 
1.2 July 2010 Corrected definition of hypoxemia in glossary of terms. 
1.3 June 2011 Added version number and version history summary. 
Summarized introduction and background sections for brevity. 
Reorganized surveillance methods section for ease of use. 
Clarified reporting of “approved deviation” incidents. 
Clarified use of “other” in adverse reaction reporting. 
Clarified use of “doubtful” or “ruled out” in adverse reaction reporting. 
Added denominator summary options to list of available analysis reports. 
Replaced < and > signs with appropriate text for. 
Added “cessation of” to time frame requirements in case definitions. 
NEW probable case definition category for allergic reaction reporting. 
Updated adult hypotensive reaction case definition to align with updated ISBT 
definition. 
NEW possible imputability category for DHTR. 
DELETED possible case definition category for hypotensive reaction. 
NEW probable imputability category for PTP reaction. 
Updated and clarified imputability categories for TAGVHD reaction. 
DELETED possible case definition category for TRALI. 
Simplified imputability criteria for TTI. 
Clarified case definition and imputability criteria for all adverse reactions. 
2.0 January 2013 Complete revision of organization and presentation of information 
Major change in incident reporting requirements. With this release, only incidents 
that relate to an adverse patient reaction are required for participation. 
Major change in adverse reaction reporting requirements. With this release, minor 
allergic reactions are no longer required for participation. 
Combined the signs/symptoms with laboratory/radiology columns in case definition 
tables for clarity. Listed criteria in alphabetical order where possible for consistency 
and clarity. Moved general severity requirements from the appendix to the criteria 
tables where they were previously missing. 
Re-ordered adverse reaction tables to put respiratory reactions first. 
Added Imputability criteria of Doubtful, Ruled Out, and Not Determined to the case 
definition tables as OPTIONAL reporting categories. The reporting is not a change, 
but including them in the table is new. They were added for clarity. 
Added specific AHTR criteria to allow for reporting of non-immune mediated 
reactions. 
Added a separate case definition table for Other and Unknown reactions. These 
categories are available for OPTONAL use. 
Removed redundant and unnecessary appendices. 
2.1 August 2013 Minor revisions to verbiage throughout for clarity. 
Added definitions and illustration of surveillance key terms in Section 1. 
Added clarification of surveillance vs. clinical definitions in Section 1. 
Added less-specific case definition categories for OPTIONAL reporting of cases 
that do not fully meet CDC case criteria for the following reactions: hypotension, 
febrile non-hemolytic, acute hemolytic and delayed hemolytic. 
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Version Release Date Summary of Revisions 
Added a possible case definition category for TTI for OPTIONAL reporting of 
syndromic cases that are not laboratory confirmed. 
2.1.1 September 2013 Updated diagram in Section 1 and added version history for v2.0 and v2.1. 
2.1.2 January 2014 Updated the incident codes in Section 4 and included required reporting of discards 
and total crossmatch procedures on the Monthly Reporting Denominators form in 
Section 5. 
2.1.3 August 2014 Added a suggested citation for the surveillance protocol in Section 1. Updated the 
acute hemolytic case definition in Section 3 for clarity. Updated the reporting 
requirements in Section 5 for clarity.   
2.2 January 2016 Updated contact instructions for consistency in Section 1: User support 
Updated version number in Section 1: Suggested Citation 
Remove Root Cause Analysis Result from Section 4: Incident Glossary 
Updated denominator report description to include Pathogen-reduced products in 
Section 5: Required Reporting 
2.3 June 2016 Updated denominator report description to include Table 3 description. 
2.4 January 2017 Section 1: Setting – Added additional Annual Facility form for Non-Acute Care Facilities to report. 
  
Section 2: Annual Facility Survey – Added information about Non-Acute Care 
Facility Annual Facility Survey, Added links to the Annual Facility Survey – Non-
Acute Care Facility form and table of instructions for clarity. 
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Section 1. Hemovigilance Module Surveillance Overview 
 
 
Purpose 
The National Healthcare Safety Network (NHSN) Hemovigilance (HV) Module was created to implement 
national surveillance of transfusion-associated adverse events aimed at improving patient safety, 
minimizing morbidity and mortality of transfusion recipients, and identifying emerging complications and 
pathogens associated with blood transfusion. 
 
Settings 
The Hemovigilance Module may be used by any U.S. healthcare facility where blood components and 
manufactured blood products are transfused (e.g., adult or pediatric facilities, acute or non-acute care 
facilities). Surveillance must be performed facility-wide, including patient care areas for emergency, 
general medical, and surgical patients; obstetrics and gynecology; orthopedics, oncology, and other 
chronic diseases; and any other facility location where transfusions are administered. 
 
Methods 
The NHSN Hemovigilance Module requires comprehensive surveillance of patients and blood 
components throughout the transfusion process, from product receipt to administration to the patient. 
Participation in the NHSN Hemovigilance Module requires reporting of all adverse transfusion reactions 
and reaction-associated incidents that occur for patients transfused at or by your facility as well as a 
monthly summary of components transfused or discarded and patient samples collected for type and 
screen or crossmatch. 
 
Data Collection 
NHSN is a web-based application used by healthcare facilities to report surveillance data. Paper 
versions of all forms are used to collect data prior to data entry in the NHSN Hemovigilance Module. The 
paper forms are available on the NHSN Blood Safety Surveillance website. A link to the appropriate 
form(s) and their instructions is provided in the following sections for your convenience. 
 
 
Training 
Training presentations are available on the NHSN Biovigilance Component website for self-paced 
training and must be reviewed prior to participating in the Hemovigilance Module. CDC also provides 
webinar and in-person training opportunities for current NHSN participants. These opportunities are 
communicated through the NHSN quarterly newsletter and emails from the Biovigilance Team. 
 
User Support 
CDC is available to answer your questions about the Surveillance Protocol and to help navigate the 
NHSN web application. Please contact us at nhsn@cdc.gov. Type BIOVIGLANCE in the subject line for 
quickest routing to the Biovigilance/Hemovigilance Team. 
 
Suggested Citation for the Hemovigilance Module Surveillance Protocol 
U.S. Centers for Disease Control and Prevention. The National Healthcare Safety Network 
(NHSN) Manual: Biovigilance Component v2.4. Atlanta, GA: Division of Healthcare Quality 
Promotion, National Center for Emerging and Zoonotic Infectious Diseases. Available at: 
http://www.cdc.gov/nhsn/PDFs/Biovigilance/BV-HV-protocol-current.pdf. Accessed [enter date].  
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Key Terms (see Fig. 1) 
 Adverse event: An unintended and undesirable occurrence before, during or after transfusion of 
blood or blood components. Adverse events include both incidents and adverse reactions. 
 Adverse reaction: An undesirable response or effect in a patient temporally associated with the 
administration of blood or blood components. It may or may not be the result of an incident. 
 Incident: Any error or accident that could affect the quality or efficacy of blood, blood components, 
or patient transfusions. It may or may not result in an adverse reaction in a transfusion recipient.  
 Near miss: A subset of incidents that are discovered before the start of a transfusion that could 
have led to a wrongful transfusion or an adverse reaction in a transfusion recipient. 
 
Data Reporting Requirements (See Fig. 1) 
 An annual facility demographic and practice survey for each calendar year of participation 
 ALL adverse reactions that follow transfusion at or by your facility 
 ALL incidents (i.e., errors or accidents) associated with an adverse reaction 
 The number of blood components transfused or discarded and patient samples collected for type 
and screen or crossmatch each month 
 
Figure 1.  Venn diagram of NHSN Hemovigilance Module surveillance terms.  
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Section 2. Hemovigilance Module Annual Facility Survey 
 
 
Required Reporting 
Participating facilities must enter the Hemovigilance Module Annual Facility Survey at the time that they 
enroll or activate the Biovigilance Component and at the beginning of each calendar year thereafter. The 
survey is used by CDC to classify facilities for appropriate comparisons in aggregate data analyses and 
to learn more about common practices among transfusion services. The data collected in the survey 
covers the previous calendar year. For example, if the facility is enrolling in NHSN for the first time in 
October of 2013, report information for January 2012-December 2012 on the first Hemovigilance Module 
Annual Facility Survey. In January 2014, complete a new survey with data from January 2013-December 
2013. CDC recommends collecting all survey information on a paper form before attempting to enter 
data into the web application.  
 
As of January 2017, non-acute care facilities will be able to report hemovigilance data to NHSN. Non-
acute care facilities should complete Annual Facility Survey for Non-acute care facility 57.306. This form 
contains questions tailored to non-acute care facilities. Users may refer to the Non-Acute Care Facility 
Table of Instructions form 57.306 for detailed instruction about data collection.  
 
 
Form 
CDC 57.300 Hemovigilance Module Annual Facility Survey - Acute Care Facility 
 
CDC 57.306 Hemovigilance Module Annual Facility Survey - Non-Acute Care Facility 
 
 
Form Instructions 
CDC 57.300 Hemovigilance Module Annual Facility Survey - Acute Care Facility Table of Instructions 
 
 
CDC 57.306 Hemovigilance Module Annual Facility Survey - Non-Acute Care Facility Table of 
Instructions 
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Section 3: Hemovigilance Module Adverse Reactions 
 
 
Required Reporting 
All CDC-defined transfusion-associated adverse reactions that are possibly, probably, or definitely 
related to a transfusion performed by the participating facility must be reported to NHSN. If a patient 
experiences more than one adverse reaction during or following the same transfusion episode, complete 
a separate form for each reaction. Adverse reaction reports should be entered into NHSN after an 
investigation of the reaction has been completed and imputability has been determined to the extent 
possible. Reports should be entered within 30 days of the month that the reaction occurred or when the 
investigation is completed. 
 
Optional Reporting 
Reporting suspected adverse reactions where imputability is determined to be doubtful or ruled out is not 
required. A facility may report reactions determined to be doubtful or ruled out in order to use NHSN to 
document transfusion reaction investigations each month. Adverse reactions that are not defined in the 
surveillance protocol may also be reported using the ‘Other’ and ‘Unknown’ adverse reaction categories; 
standard severity and imputability criteria are provided for that purpose.  
 
Adverse Reaction Classification 
Each CDC-defined transfusion-associated adverse reaction must be classified according to the reaction-
specific case definition, severity, and imputability criteria printed in this section of the protocol. It is 
imperative that every facility classify adverse reactions according to protocol definitions. Accurate 
classification will usually require a detailed review of the patient record.  
 
Surveillance definitions are distinctly different from clinical definitions. Surveillance definitions are 
designed to capture data consistently and reliably in order to identify trends and inform quality 
improvement practices. The surveillance definitions are not intended as clinical diagnostic criteria or to 
provide treatment guidance. The Biovigilance Team is working to provide users with access to aggregate 
data for bench marking purposes.   
 
Defined Adverse Reactions 
 Transfusion-associated circulatory overload (TACO) 
 Transfusion-related acute lung injury (TRALI) 
 Transfusion-associated dyspnea (TAD) 
 Allergic reaction (where severity is severe, life threatening, or death) 
 Hypotensive transfusion reaction 
 Febrile non-hemolytic transfusion reaction (FNHTR) 
 Acute hemolytic transfusion reaction (AHTR) 
 Delayed hemolytic transfusion reaction (DHTR) 
 Delayed serologic transfusion reaction (DSTR) 
 Transfusion-associated graft vs. host disease (TAGVHD) 
 Post-transfusion purpura (PTP) 
 Transfusion-transmitted infection (TTI) 
 
 
Form 
Adverse reaction forms are available at the NHSN Blood Safety Surveillance website.  
 
Form Instructions 
Each Adverse Reaction form’s Table of Instructions is available at the NHSN Blood Safety Surveillance 
website.  
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Adverse Reaction Case Classification Criteria Tables 
 
Transfusion-associated circulatory overload (TACO) 
 
Case Definition Severity Imputability 
Definitive: 
New onset or exacerbation 
of 3 or more of the 
following within 6 hours of 
cessation of transfusion: 
 Acute respiratory 
distress (dyspnea, 
orthopnea, cough) 
 Elevated brain 
natriuretic peptide 
(BNP) 
 Elevated central 
venous pressure 
(CVP) 
 Evidence of left heart 
failure 
 Evidence of positive 
fluid balance 
 Radiographic 
evidence of 
pulmonary edema 
 
 
Probable: 
N/A 
 
 
Possible: 
N/A 
Non-severe: 
Medical intervention (e.g. symptomatic 
treatment) is required but lack of such would 
not result in permanent damage or 
impairment of a bodily function. 
 
 
Severe: 
Inpatient hospitalization or prolongation of 
hospitalization is directly attributable to the 
adverse reaction, persistent or significant 
disability or incapacity of the patient occurs 
as a result of the reaction, or a medical or 
surgical intervention is necessary to 
preclude permanent damage or impairment 
of a body function. 
 
 
Life-threatening: 
Major intervention required following the 
transfusion (e.g. vasopressors, intubation, 
transfer to intensive care) to prevent death. 
 
 
Death: 
The recipient died as a result of the 
adverse transfusion reaction. Death 
should be used if death is possibly, 
probably or definitely related to 
transfusion. If the patient died of a cause 
other than the transfusion, the severity of the 
reaction should be graded as appropriate 
given the clinical circumstances related to 
the reaction. 
 
 
Not Determined: 
The severity of the adverse reaction is 
unknown or not stated. 
Definite: 
No other explanations for circulatory 
overload are possible. 
 
 
Probable: 
Transfusion is a likely contributor to 
circulatory overload 
AND EITHER 
The patient received other fluids as 
well 
OR 
The patient has a history of cardiac 
insufficiency that could explain the 
circulatory overload, but 
transfusion is just as likely to have 
caused the circulatory overload. 
 
 
Possible: 
The patient has a history of pre-
existing cardiac insufficiency that 
most likely explains circulatory 
overload. 
 
OPTIONAL 
Doubtful: 
Evidence is clearly in favor of a 
cause other than the transfusion, but 
transfusion cannot be excluded. 
 
 
Ruled Out: 
There is conclusive evidence beyond 
reasonable doubt of a cause other 
than the transfusion. 
 
 
Not Determined: 
The relationship between the 
adverse reaction and the transfusion 
is unknown or not stated. 
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Transfusion-related acute lung injury (TRALI) 
 
Case Definition Severity Imputability 
Definitive: 
NO evidence of acute lung 
injury (ALI) prior to 
transfusion 
AND 
ALI onset during or within 
6 hours of cessation of 
transfusion 
AND 
Hypoxemia defined by any 
of these methods: 
 PaO2/FiO2  less than 
or equal to 300 mm 
Hg  
 Oxygen saturation 
less than 90% on 
room air  
 Other clinical 
evidence 
AND 
Radiographic evidence of 
bilateral infiltrates 
AND 
No evidence of left atrial 
hypertension (i.e., 
circulatory overload) 
 
 
Probable: 
N/A 
 
 
Possible: 
N/A 
Non-severe: 
Medical intervention (e.g. 
symptomatic treatment) is required 
but lack of such would not result in 
permanent damage or impairment of 
a bodily function. 
 
 
Severe: 
Inpatient hospitalization or 
prolongation of hospitalization is 
directly attributable to the adverse 
reaction, persistent or significant 
disability or incapacity of the patient 
occurs as a result of the reaction, or a 
medical or surgical intervention is 
necessary to preclude permanent 
damage or impairment of a body 
function. 
 
 
Life-threatening: 
Major intervention required following 
the transfusion (e.g. vasopressors, 
intubation, transfer to intensive care) 
to prevent death. 
 
 
Death: 
The recipient died as a result of the 
adverse transfusion reaction. 
Death should be used if death is 
possibly, probably or definitely 
related to transfusion. If the patient 
died of a cause other than the 
transfusion, the severity of the 
reaction should be graded as 
appropriate given the clinical 
circumstances related to the reaction. 
 
 
Not Determined: 
The severity of the adverse reaction 
is unknown or not stated. 
Definite: 
There are no alternative risk factors for ALI 
present. 
 
 
Probable: 
N/A 
 
 
Possible: 
There is evidence of other causes for acute 
lung injury such as: 
 
Direct Lung Injury 
 Aspiration 
 Pneumonia 
 Toxic inhalation 
 Lung contusion 
 Near drowning 
 
Indirect Lung Injury 
 Severe sepsis 
 Shock 
 Multiple trauma 
 Burn injury 
 Acute pancreatitis 
 Cardiopulmonary bypass 
 Drug overdose 
 
OPTIONAL 
Doubtful: 
Evidence is clearly in favor of a cause other 
than the transfusion, but transfusion cannot 
be excluded. 
 
 
Ruled Out: 
There is conclusive evidence beyond 
reasonable doubt of a cause other than the 
transfusion.  
 
 
Not Determined: 
The relationship between the adverse 
reaction and the transfusion is unknown or 
not stated. 
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Transfusion-associated dyspnea (TAD) 
 
Case Definition Severity Imputability 
Definitive: 
Acute respiratory 
distress occurring within 
24 hours of cessation of 
transfusion 
AND 
Allergic reaction, TACO, 
and TRALI definitions 
are not applicable. 
 
 
Probable: 
N/A 
 
 
Possible: 
N/A 
Non-severe: 
Medical intervention (e.g. symptomatic treatment) 
is required but lack of such would not result in 
permanent damage or impairment of a bodily 
function. 
 
 
Severe: 
Inpatient hospitalization or prolongation of 
hospitalization is directly attributable to the 
adverse reaction, persistent or significant disability 
or incapacity of the patient occurs as a result of 
the reaction, or a medical or surgical intervention 
is necessary to preclude permanent damage or 
impairment of a body function. 
 
 
Life-threatening: 
Major intervention required following the 
transfusion (e.g. vasopressors, intubation, transfer 
to intensive care) to prevent death. 
 
 
Death: 
The recipient died as a result of the adverse 
transfusion reaction. Death should be used if 
death is possibly, probably or definitely related 
to transfusion. If the patient died of a cause other 
than the transfusion, the severity of the reaction 
should be graded as appropriate given the clinical 
circumstances related to the reaction. 
 
 
Not Determined: 
The severity of the adverse reaction is unknown 
or not stated. 
Definite: 
Patient has no other conditions 
that could explain symptoms. 
 
 
Probable: 
There are other potential causes 
that could explain symptoms, but 
transfusion is the most likely 
cause. 
 
 
Possible: 
Other present causes are most 
likely, but transfusion cannot be 
ruled out. 
 
OPTIONAL 
Doubtful: 
Evidence is clearly in favor of a 
cause other than the transfusion, 
but transfusion cannot be 
excluded. 
 
 
Ruled Out: 
There is conclusive evidence 
beyond reasonable doubt of a 
cause other than the transfusion. 
 
 
Not Determined: 
The relationship between the 
adverse reaction and the 
transfusion is unknown or not 
stated. 
NHSN Biovigilance Component 
Hemovigilance Module Surveillance Protocol v2.4 
www.cdc.gov/nhsn 
 
 
 
 
 
Page 12 of 30 
January 2017 
Allergic reaction 
Note:  Minor allergic reactions (Non-severe) do not have to be reported to NHSN. 
 
Case Definition Severity Imputability 
Definitive: 
2 or more of the following 
occurring during or within 4 
hours of cessation of 
transfusion: 
 Conjunctival edema 
 Edema of lips, tongue and 
uvula 
 Erythema and edema of 
the periorbital area 
 Generalized flushing 
 Hypotension 
 Localized angioedema 
 Maculopapular rash 
 Pruritus (itching) 
 Respiratory distress; 
bronchospasm 
 Urticaria (hives) 
 
 
Probable: 
ANY 1 of the following occurring 
during or within 4 hours of 
cessation of transfusion: 
 Conjunctival edema 
 Edema of lips, tongue and 
uvula 
 Erythema and edema of 
the periorbital area 
 Localized angioedema 
 Maculopapular rash 
 Pruritus (itching) 
 Urticaria (hives) 
 
Severe, Life-threatening, Death: 
Involves respiratory and/or cardiovascular 
systems and presents like an anaphylactic 
reaction. There is anaphylaxis when, in 
addition to mucocutaneous symptoms, 
there are airway symptoms, hypotension, 
or associated symptoms like hypotonia 
and syncope. The respiratory signs and 
symptoms may be laryngeal (tightness in 
the throat, dysphagia, dysphonia, 
hoarseness, stridor) or pulmonary 
(dyspnea, cough, wheezing, 
bronchospasm, hypoxemia). Such a 
reaction usually occurs during or shortly 
after cessation of transfusion.  
 
 
Death should be used if death is 
possibly, probably or definitely related 
to transfusion. If the patient died of a 
cause other than the transfusion, the 
severity of the reaction should be graded 
as appropriate given the clinical 
circumstances related to the reaction. 
 
 
Not Determined: 
The severity of the adverse reaction is 
unknown or not stated. 
Definite: 
Occurs during or within 2 hours of 
cessation of transfusion 
AND 
No other evidence of 
environmental, drug or dietary 
risks. 
 
 
Probable: 
Occurs during or within 2 hours of 
cessation of transfusion 
AND 
There are other potential causes 
present that could explain 
symptoms, but transfusion is the 
most likely cause. 
 
 
Possible: 
Occurs 2 - 4 hours after cessation 
of transfusion 
OR 
Other present causes are most 
likely, but transfusion cannot be 
ruled out. 
OPTIONAL OPTIONAL OPTIONAL 
Possible: 
N/A 
Non-severe: 
There is no immediate risk to the life of 
the patient, and the patient responds 
quickly to symptomatic treatment. 
Doubtful: 
Evidence is clearly in favor of a 
cause other than the transfusion, 
but transfusion cannot be 
excluded. 
 
Ruled Out: 
There is conclusive evidence 
beyond reasonable doubt of a 
cause other than the transfusion. 
 
Not Determined: 
The relationship between the 
adverse reaction and the 
transfusion is unknown or not 
stated. 
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Hypotensive transfusion reaction 
 
Case Definition Severity Imputability 
Definitive: 
All other adverse reactions 
presenting with hypotension are 
excluded  
AND 
Hypotension occurs during or 
within 1 hour after cessation of 
transfusion. 
 
 Adults (18 years and 
older): 
Drop in systolic BP of 
greater than or equal to 30 
mmHg and systolic BP 
less than or equal to 80 
mmHg. 
 
 Infants, children and 
adolescents (1 year to 
less than 18 years old): 
Greater than 25% drop in 
systolic BP from baseline 
(e.g., drop in systolic BP of 
120mmHg to below 
90mmHg).  
 
 Neonates and small 
infants (less than 1 year 
old OR any age and less 
than 12 kg body weight): 
Greater than 25% drop in 
baseline value using 
whichever measurement is 
being recorded (e.g., mean 
BP). 
 
 
Probable: 
N/A 
 
Non-severe: 
The recipient required no 
more than discontinuation of 
transfusion and symptom 
management and no long-
term morbidity resulted from 
the reaction. 
 
 
Severe: 
Inpatient hospitalization or 
prolongation of 
hospitalization is directly 
attributable to hypotension, 
or hypotension led directly to 
long-term morbidity (e.g., 
brain damage) 
AND 
Vasopressors were not 
required. 
 
 
Life-threatening: 
The recipient required 
vasopressors. 
 
 
Death: 
The recipient died as a 
result of the adverse 
transfusion reaction. 
Death should be used if 
death is possibly, probably 
or definitely related to 
transfusion. If the patient 
died of a cause other than 
the transfusion, the severity 
of the reaction should be 
graded as appropriate given 
the clinical circumstances 
related to the reaction. 
 
 
Not Determined: 
The severity of the adverse 
reaction is unknown or not 
stated. 
Definite: 
Occurs less than 15 minutes after the start of 
the transfusion 
AND 
Responds rapidly (i.e., within 10 minutes) to 
cessation of transfusion and supportive 
treatment 
AND 
The patient has no other conditions that could 
explain hypotension. 
 
 
Probable: 
Onset is between 15 minutes after start and 1 
hour after cessation of transfusion 
OR 
The patient does not respond rapidly to 
cessation of transfusion and supportive 
treatment 
OR 
There are other potential causes present that 
could explain hypotension, but transfusion is 
the most likely cause. 
 
 
Possible: 
Other conditions that could readily explain 
hypotension are present. 
OPTIONAL OPTIONAL 
Possible: 
Hypotension occurs, does not 
meet the criteria above. Other, 
more specific reaction definitions 
do not apply.  
Doubtful: 
Evidence is clearly in favor of a cause other 
than the transfusion, but transfusion cannot be 
excluded. 
 
Ruled Out: 
There is conclusive evidence beyond 
reasonable doubt of a cause other than the 
transfusion. 
 
Not Determined: 
The relationship between the adverse reaction 
and the transfusion is unknown or not stated. 
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Febrile non-hemolytic transfusion reaction (FNHTR) 
Note:  Reactions may be classified as FNHTRs in the absence of fever if chills or rigors occur. 
 
Case Definition Severity Imputability 
Definitive: 
Occurs during or within 4 
hours of cessation of 
transfusion 
AND EITHER 
Fever (greater than or 
equal to 38°C/100.4°F 
oral and a change of at 
least 1°C/1.8°F) from pre-
transfusion value 
OR 
Chills/rigors are present. 
 
 
Probable: 
N/A 
Non-severe: 
Medical intervention (e.g. symptomatic 
treatment) is required but lack of such would 
not result in permanent damage or impairment 
of a bodily function. 
 
 
Severe: 
Inpatient hospitalization or prolongation of 
hospitalization is directly attributable to the 
adverse reaction, persistent or significant 
disability or incapacity of the patient occurs as 
a result of the reaction, or a medical or surgical 
intervention is necessary to preclude 
permanent damage or impairment of a body 
function. 
 
 
Life-threatening: 
Major intervention required following the 
transfusion (e.g. vasopressors, intubation, 
transfer to intensive care) to prevent death. 
 
 
Death: 
The recipient died as a result of the adverse 
transfusion reaction. Death should be used if 
death is possibly, probably or definitely 
related to transfusion. If the patient died of a 
cause other than the transfusion, the severity 
of the reaction should be graded as 
appropriate given the clinical circumstances 
related to the reaction. 
 
 
Not Determined: 
The severity of the adverse reaction is 
unknown or not stated. 
Definite: 
Patient has no other conditions 
that could explain 
signs/symptoms. 
 
 
Probable: 
There are other potential causes 
present that could explain 
signs/symptoms, but transfusion 
is the most likely cause. 
 
 
Possible: 
Other present causes are most 
likely, but transfusion cannot be 
ruled out. 
OPTIONAL OPTIONAL 
Possible: 
FNHTR is suspected, but 
reported symptoms and/or 
available information are 
not sufficient to meet the 
criteria defined above. 
Other, more specific 
adverse reaction definitions 
do not apply. 
Doubtful: 
Evidence is clearly in favor of a 
cause other than the transfusion, 
but transfusion cannot be 
excluded. 
 
 
Ruled Out: 
There is conclusive evidence 
beyond reasonable doubt of a 
cause other than the transfusion.  
 
 
Not Determined: 
The relationship between the 
adverse reaction and the 
transfusion is unknown or not 
stated. 
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Acute hemolytic transfusion reaction (AHTR) 
Note:  Report hemolytic reactions resulting from immune or non-immune causes, including when the 
recipient is intentionally transfused with incompatible blood components. 
Case Definition Severity Imputability 
Definitive: 
Occurs during, or within 24 hours of cessation of 
transfusion with new onset of ANY of the following 
signs/symptoms: 
 Back/flank pain 
 Chills/rigors 
 Disseminated intravascular coagulation (DIC) 
 Epistaxis 
 Fever 
 Hematuria (gross visual hemolysis) 
 Hypotension 
 Oliguria/anuria 
 Pain and/or oozing at IV site 
 Renal failure 
AND 
2 or more of the following: 
 Decreased fibrinogen 
 Decreased haptoglobin 
 Elevated bilirubin 
 Elevated LDH 
 Hemoglobinemia  
 Hemoglobinuria 
 Plasma discoloration c/w hemolysis 
 Spherocytes on blood film 
AND EITHER 
(IMMUNE-MEDIATED) 
Positive direct antiglobulin test (DAT) for anti-IgG or 
anti-C3 
AND 
Positive elution test with alloantibody present on the 
transfused red blood cells 
OR 
(NON-IMMUNE MEDIATED) 
Serologic testing is negative, and physical cause (e.g., 
thermal, osmotic, mechanical, chemical) is confirmed. 
 
Probable: 
Meets signs and symptoms criteria for acute hemolysis 
AND EITHER 
(IMMUNE MEDIATED) 
Physical cause is excluded but serologic evidence is not 
sufficient to meet definitive criteria  
OR 
(NON-IMMUNE MEDIATED) 
Physical cause is suspected and serologic testing is 
negative. 
Non-severe: 
Medical intervention (e.g. 
symptomatic treatment) is 
required but lack of such would 
not result in permanent 
damage or impairment of a 
bodily function. 
 
 
Severe: 
Inpatient hospitalization or 
prolongation of hospitalization 
is directly attributable to the 
adverse reaction, persistent or 
significant disability or 
incapacity of the patient occurs 
as a result of the reaction, or a 
medical or surgical intervention 
is necessary to preclude 
permanent damage or 
impairment of a body function. 
 
 
Life-threatening: 
Major intervention required 
following the transfusion (e.g. 
vasopressors, intubation, 
transfer to intensive care) to 
prevent death. 
 
 
Death: 
The recipient died as a result 
of the adverse transfusion 
reaction. Death should be 
used if death is possibly, 
probably or definitely related 
to transfusion. If the patient 
died of a cause other than the 
transfusion, the severity of the 
reaction should be graded as 
appropriate given the clinical 
circumstances related to the 
reaction. 
 
 
Not Determined: 
The severity of the adverse 
reaction is unknown or not 
stated. 
Definite: 
ABO or other allotypic 
RBC antigen 
incompatibility is known 
OR 
Only transfusion-related 
(i.e., immune or non-
immune) cause of acute 
hemolysis is present. 
 
 
Probable: 
There are other 
potential causes 
present that could 
explain acute 
hemolysis, but 
transfusion is the most 
likely cause. 
 
 
Possible: 
Other causes of acute 
hemolysis are more 
likely, but transfusion 
cannot be ruled out. 
 
OPTIONAL 
Doubtful: 
Evidence is clearly in 
favor of a cause other 
than the transfusion, but 
transfusion cannot be 
excluded. 
 
 
Ruled Out: 
There is conclusive 
evidence beyond 
reasonable doubt of a 
cause other than the 
transfusion.  
 
 
Not Determined: 
The relationship 
between the adverse 
reaction and the 
transfusion is unknown 
or not stated. 
OPTIONAL 
Possible: 
AHTR is suspected within 24 hours of cessation of 
transfusion, but symptoms, test results, and/or information 
are not sufficient to meet the criteria defined above. Other, 
more specific adverse definitions do not apply. 
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Delayed hemolytic transfusion reaction (DHTR) 
Note:  Report all hemolytic reactions, including when the recipient is intentionally transfused with 
incompatible blood components. 
 
Case Definition Severity Imputability 
Definitive: 
Positive direct antiglobulin test (DAT) 
for antibodies developed between 24 
hours and 28 days after cessation of 
transfusion 
AND EITHER 
Positive elution test with 
alloantibody present on the 
transfused red blood cells 
OR 
Newly-identified red blood cell 
alloantibody in recipient serum 
AND EITHER 
Inadequate rise of post-transfusion 
hemoglobin level or rapid fall in 
hemoglobin back to pre-transfusion 
levels 
OR 
Otherwise unexplained appearance 
of spherocytes. 
 
 
Probable: 
Newly-identified red blood cell 
alloantibody demonstrated between 
24 hours and 28 days after cessation 
of transfusion 
BUT 
Incomplete laboratory evidence to 
meet definitive case definition criteria. 
 
 
NOTE: Patient may be asymptomatic 
or have symptoms that are similar to 
but milder than AHTR; symptoms are 
not required to meet case definition 
criteria. 
Non-severe: 
Medical intervention (e.g. 
symptomatic treatment) is 
required but lack of such would 
not result in permanent damage 
or impairment of a bodily 
function. 
 
 
Severe: 
Inpatient hospitalization or 
prolongation of hospitalization is 
directly attributable to the 
adverse reaction, persistent or 
significant disability or incapacity 
of the patient occurs as a result 
of the reaction, or a medical or 
surgical intervention is necessary 
to preclude permanent damage 
or impairment of a body function. 
 
 
Life-threatening: 
Major intervention required 
following the transfusion (e.g. 
vasopressors, intubation, transfer 
to intensive care) to prevent 
death. 
 
 
Death: 
The recipient died as a result of 
the adverse transfusion 
reaction. Death should be used 
if death is possibly, probably or 
definitely related to transfusion. 
If the patient died of a cause 
other than the transfusion, the 
severity of the reaction should be 
graded as appropriate given the 
clinical circumstances related to 
the reaction. 
 
 
Not Determined: 
The severity of the adverse 
reaction is unknown or not 
stated. 
Definite: 
No other explanation for symptoms 
or newly-identified antibody is 
present. 
 
 
Probable: 
An alternate explanation for 
symptoms or newly-identified 
antibody is present, but transfusion is 
the most likely cause. 
 
 
Possible: 
Other explanations for symptoms or 
newly-identified antibody are more 
likely, but transfusion cannot be ruled 
out. 
OPTIONAL OPTIONAL 
Possible: 
DHTR is suspected, but reported 
symptoms, test results, and/or 
available information are not sufficient 
to meet the criteria defined above. 
Other, more specific adverse reaction 
definitions do not apply. 
Doubtful: 
Evidence is clearly in favor of a 
cause other than the transfusion, but 
transfusion cannot be excluded. 
 
Ruled Out: 
There is conclusive evidence beyond 
reasonable doubt of a cause other 
than the transfusion. 
 
Not Determined: 
The relationship between the 
adverse reaction and the transfusion 
is unknown or not stated. 
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Delayed serologic transfusion reaction (DSTR) 
Note: Delayed serologic reactions should only be reported for patients transfused by your facility. 
 
Case Definition Severity Imputability 
Definitive: 
Absence of clinical signs 
of hemolysis 
AND 
Demonstration of new, 
clinically-significant 
antibodies against red 
blood cells  
BY EITHER 
Positive direct 
antiglobulin test (DAT)  
OR 
Positive antibody 
screen with newly 
identified RBC 
alloantibody. 
 
 
Probable: 
N/A 
 
 
Possible: 
N/A 
Not Determined: 
Since this is by definition a 
reaction with no clinical 
symptoms, severity of the 
reaction cannot be 
graded. 
Definite: 
New alloantibody is identified between 24 hours and 28 
days after cessation of transfusion  
AND 
Transfusion performed by your facility is the only 
possible cause for seroconversion. 
 
 
Probable: 
New alloantibody is identified between 24 hours and 28 
days after cessation of transfusion 
AND 
The patient has other exposures (e.g. transfusion by 
another facility or pregnancy) that could explain 
seroconversion, but transfusion by your facility is the 
most likely cause. 
 
 
Possible: 
New alloantibody is identified between 24 hours and 28 
days after cessation of transfusion 
AND 
The patient was transfused by your facility, but other 
exposures are present that most likely explain 
seroconversion. 
 
OPTIONAL 
Doubtful: 
Evidence is clearly in favor of a cause other than the 
transfusion, but transfusion cannot be excluded. 
 
 
Ruled Out: 
There is conclusive evidence beyond reasonable doubt 
of a cause other than the transfusion.  
 
 
Not Determined: 
The relationship between the adverse reaction and the 
transfusion is unknown or not stated. 
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Transfusion-associated graft vs. host disease (TAGVHD) 
 
Case Definition Severity Imputability 
Definitive: 
A clinical syndrome occurring from 
2 days to 6 weeks after cessation of 
transfusion characterized by: 
 Characteristic rash: 
erythematous, maculopapular 
eruption centrally that spreads 
to extremities and may, in 
severe cases, progress to 
generalized erythroderma and 
hemorrhagic bullous 
formation. 
 Diarrhea 
 Fever 
 Hepatomegaly 
 Liver dysfunction (i.e., 
elevated ALT, AST, Alkaline 
phosphatase, and bilirubin) 
 Marrow aplasia 
 Pancytopenia 
AND 
Characteristic histological 
appearance of skin or liver biopsy. 
 
 
Probable: 
Meets definitive criteria  
EXCEPT 
Biopsy negative or not done. 
 
 
Possible: 
N/A 
Non-severe: 
N/A 
 
 
Severe: 
Patient had marked 
symptoms and responded to 
treatment. 
 
 
Life-threatening: 
Patient had severe symptoms 
and required life-saving 
treatment (e.g., 
immunosuppression). 
 
 
Death: 
The recipient died as a result 
of the adverse transfusion 
reaction. Death should be 
used if death is possibly, 
probably or definitely 
related to transfusion. If the 
patient died of a cause other 
than the transfusion, the 
severity of the reaction should 
be graded as appropriate 
given the clinical 
circumstances related to the 
reaction. 
 
 
Not Determined: 
The severity of the adverse 
reaction is unknown or not 
stated. 
Definite: 
WBC chimerism present in the absence of 
alternative diagnoses. 
 
 
Probable: 
WBC chimerism present 
BUT 
Other potential causes are present (e.g., 
stem cell transplantation). 
 
 
Possible:  
WBC chimerism not present or not done 
OR 
Alternative explanations are more likely 
(e.g., solid organ transplantation). 
 
OPTIONAL 
Doubtful: 
Evidence is clearly in favor of a cause 
other than the transfusion, but transfusion 
cannot be excluded. 
 
 
Ruled Out: 
There is conclusive evidence beyond 
reasonable doubt of a cause other than 
the transfusion.  
 
 
Not Determined: 
The relationship between the adverse 
reaction and the transfusion is unknown or 
not stated. 
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Post transfusion purpura (PTP) 
 
Case Definition Severity Imputability 
Definitive: 
Alloantibodies in the patient 
directed against HPA or other 
platelet specific antigen detected 
at or after development of 
thrombocytopenia 
AND 
Thrombocytopenia (i.e., decrease 
in platelets to less than 20% of 
pre-transfusion count). 
 
 
Probable: 
Alloantibodies in the patient 
directed against HPA or other 
platelet specific antigen detected 
at or after development of 
thrombocytopenia. 
AND 
Decrease in platelets to levels 
between 20% and 80% of pre-
transfusion count. 
 
Non-severe: 
Medical intervention (e.g. symptomatic 
treatment) is required but lack of such 
would not result in permanent damage 
or impairment of a bodily function. 
 
 
Severe: 
Inpatient hospitalization or 
prolongation of hospitalization is 
directly attributable to the adverse 
reaction, persistent or significant 
disability or incapacity of the patient 
occurs as a result of the reaction, or a 
medical or surgical intervention is 
necessary to preclude permanent 
damage or impairment of a body 
function. 
 
 
Life-threatening: 
Major intervention required following 
the transfusion (e.g. vasopressors, 
intubation, transfer to intensive care) to 
prevent death. 
 
 
Death: 
The recipient died as a result of the 
adverse transfusion reaction. Death 
should be used if death is possibly, 
probably or definitely related to 
transfusion. If the patient died of a 
cause other than the transfusion, the 
severity of the reaction should be 
graded as appropriate given the 
clinical circumstances related to the 
reaction. 
 
 
Not Determined: 
The severity of the adverse reaction is 
unknown or not stated. 
Definite:  
Occurs 5-12 days post-transfusion 
AND 
Patient has no other conditions to 
explain thrombocytopenia. 
 
 
Probable: 
Occurs less than 5 or more than 
12 days post-transfusion 
OR 
There are other potential causes 
present that could explain 
thrombocytopenia, but transfusion 
is the most likely cause. 
 
 
Possible: 
Alternate explanations for 
thrombocytopenia are more likely, 
but transfusion cannot be ruled 
out. 
 
OPTIONAL OPTIONAL 
Possible:  
PTP is suspected, but laboratory 
findings and/or information are not 
sufficient to meet defined criteria 
above. For example, the patient 
has a drop in platelet count to less 
than 80% of pre-transfusion count 
but HPA antibodies were not 
tested or were negative. Other, 
more specific adverse reaction 
definitions do not apply. 
Doubtful: 
Evidence is clearly in favor of a 
cause other than the transfusion, 
but transfusion cannot be 
excluded. 
 
 
Ruled Out: 
There is conclusive evidence 
beyond reasonable doubt of a 
cause other than the transfusion.  
 
 
Not Determined: 
The relationship between the 
adverse reaction and the 
transfusion is unknown or not 
stated. 
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Transfusion-transmitted infection (TTI) 
Case Definition Severity Imputability 
Definitive: 
Laboratory 
evidence of a 
pathogen in the 
transfusion 
recipient. 
 
 
Probable: 
N/A 
Non-severe: 
Medical intervention 
(e.g. symptomatic 
treatment) is required 
but lack of such 
would not result in 
permanent damage 
or impairment of a 
bodily function. 
 
 
Severe: 
Inpatient 
hospitalization or 
prolongation of 
hospitalization is 
directly attributable to 
the adverse reaction, 
persistent or 
significant disability or 
incapacity of the 
patient occurs as a 
result of the reaction, 
or a medical or 
surgical intervention 
is necessary to 
preclude permanent 
damage or 
impairment of a body 
function. 
 
 
Life-threatening: 
Major intervention 
required following the 
transfusion (e.g. 
vasopressors, 
intubation, transfer to 
intensive care) to 
prevent death. 
 
 
Death: 
The recipient died as 
a result of the 
adverse transfusion 
reaction.  
 
 
Not Determined: 
The severity of the 
adverse reaction is 
unknown or not 
stated. 
Definite: 
ONE or more of the following: 
 Evidence of the pathogen in the transfused component 
 Evidence of the pathogen in the donor at the time of donation 
 Evidence of the pathogen in an additional component from the same donation 
 Evidence of the pathogen in an additional recipient of a component from the 
same donation 
AND 
No other potential exposures to the pathogen could be identified in the recipient. 
AND EITHER 
Evidence that the recipient was not infected with the pathogen prior to transfusion 
OR 
Evidence that the identified pathogen strains are related by molecular or extended 
phenotypic comparison testing with statistical confidence (p<0.05). 
 
Probable: 
ONE or more of the following: 
 Evidence of the pathogen in the transfused component 
 Evidence of the pathogen in the donor at the time of donation 
 Evidence of the pathogen in an additional component from the same donation 
 Evidence of the pathogen in an additional recipient of a component from the 
same donation. 
AND EITHER: 
Evidence that the recipient was not infected with this pathogen prior to transfusion 
OR 
No other potential exposures to the pathogen could be identified in the recipient. 
 
Possible: 
Case fails to meet definite, probable, doubtful, or ruled out imputability criteria. 
OPTIONAL OPTIONAL 
Possible: 
Temporally 
associated 
unexplained 
clinical illness 
consistent with 
infection, but no 
pathogen is 
detected in the 
recipient. Other, 
more specific 
adverse reactions 
are ruled out. 
 
Note:  Possible 
cases cannot meet 
the definite or 
probable 
imputability criteria. 
Doubtful: 
Laboratory evidence that the recipient was infected with this pathogen prior to 
transfusion  
OR 
Evidence is clearly in favor of a cause other than transfusion, but transfusion cannot 
be excluded. 
 
Ruled Out: 
ALL of the following (where applicable):  
 Evidence that the transfused component was negative for this pathogen at the 
time of transfusion 
 Evidence that the donor was negative for this pathogen at the time of donation 
 Evidence that additional components from the same donation were negative 
for this pathogen 
OR 
There is conclusive evidence beyond reasonable doubt of a cause other than the 
transfusion. 
 
Not Determined: 
The relationship between the adverse reaction and the transfusion is unknown or 
not stated. 
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Transfusion-transmitted infection (TTI) 
(continued) 
 
Pathogens of well-documented importance in blood safety. 
These pathogens have public health significance for hemovigilance, are well-documented blood stream 
pathogens, and/or are routinely screened for in blood donors. A full list of potentially infectious organisms is 
available in the drop-down pathogen list in NHSN. 
Bacterial Viral Parasitic Other 
Enterobacter cloacae 
Escherichia coli 
Klebsiella oxytoca 
Klebsiella pneumoniae 
Pseudomonas aeruginosa 
Serratia marcescens 
Staphylococcus aureus 
Staphylococcus 
epidermidis 
Staphylococcus 
lugdunensis 
Syphilis (Treponema 
pallidum) 
Yersinia enterocolitica 
Cytomegalovirus (CMV) 
Enterovirus spp. 
Epstein Barr (EBV) 
Hepatitis A 
Hepatitis B 
Hepatitis C 
Human Immunodeficiency Virus 1 
(HIV-1) 
Human Immunodeficiency Virus 2 
(HIV-2) 
Human Parvovirus B-19 
Human T-Cell Lymphotropic 
Virus-1 (HTLV-1) 
Human T-Cell Lymphotropic 
Virus-2 (HTLV-2) 
West Nile Virus (WNV) 
Zika Virus (ZIKAVI) 
Babesiosis (Babesia spp.) 
Chagas disease 
(Trypanosoma cruzi)  
Malaria (Plasmodium spp.) 
 
Creutzfeldt-
Jakob Disease, 
Variant (vCJD) 
 
 
Investigation triggers for potential transfusion-transmitted infections: 
1. Identification by testing (e.g., gram stain, other smear/staining, culture, or other method) of a 
bacterial, mycobacterial, or fungal pathogen in a recipient within the time period from exposure 
(i.e., transfusion) to onset of infection appropriate for the suspected pathogen. 
 
2. Identification of an unexpected virus in the transfusion recipient by testing (e.g., culture, direct 
fluorescent antibody, or polymerase chain reaction) within the time period from exposure (i.e., 
transfusion) to onset of infection appropriate for the suspected virus. 
 
3. Identification of an unexpected parasite in the recipient by testing (e.g., blood smear, 
histopathology, serologic testing, or polymerase chain reaction) within the time period from 
exposure (i.e., transfusion) to onset of infection appropriate for the suspected parasite. 
 
4. Any of the above laboratory findings in the recipient unit upon residual testing. 
 
5. Unexplained clinical events occurring after transfusion that are consistent with transfusion-
transmitted infection, such as: 
a. Encephalitis, meningitis, or other unexplained central nervous system abnormalities. 
b. Sepsis with or without multi-organ system dysfunction. 
c. Hemolytic anemia and/or fever (e.g., in cases of transfusion-associated babesiosis or malaria). 
d. Recipient death. 
 
6. For pathogens routinely screened in the blood donor, any infection in the recipient occurring within 
6 months after transfusion if: 
a. The index donation testing was negative but 
b. The donor was subsequently found to be infected, and 
c. The recipient had no pre-transfusion history of the same infection. 
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Other or Unknown 
 
Other:  Use this option if the recipient experienced an adverse reaction that is not defined in the Hemovigilance 
Module surveillance protocol (e.g., transfusion-associated acute gut injury (TRAGI), transfusion-associated 
immunomodulation (TRIM), iron overload, microchimerism, hyperkalemia, thrombosis). 
 
Unknown:  Use this category if the patient experienced transfusion-related symptoms, but the medical event that 
caused those symptoms could not be classified. 
 
Note:  Reporting ‘Other’ and ‘Unknown’ reactions is not required by CDC.  
 
REPORTING OPTIONAL 
Case Definition Severity Imputability 
Not Applicable: 
CDC does not 
specifically define the 
‘Other’ or ‘Unknown’ 
adverse reaction 
categories, therefore 
the case definition 
criteria may only be 
reported as N/A. 
Non-severe: 
Medical intervention (e.g. symptomatic treatment) 
is required but lack of such would not result in 
permanent damage or impairment of a bodily 
function. 
 
 
Severe: 
Inpatient hospitalization or prolongation of 
hospitalization is directly attributable to the 
adverse reaction, persistent or significant disability 
or incapacity of the patient occurs as a result of 
the reaction, or a medical or surgical intervention 
is necessary to preclude permanent damage or 
impairment of a body function. 
 
 
Life-threatening: 
Major intervention required following the 
transfusion (e.g. vasopressors, intubation, transfer 
to intensive care) to prevent death. 
 
 
Death: 
The recipient died as a result of the adverse 
transfusion reaction. Death should be used if 
death is possibly, probably or definitely related 
to transfusion. If the patient died of a cause other 
than the transfusion, the severity of the reaction 
should be graded as appropriate given the clinical 
circumstances related to the reaction. 
 
 
Not Determined: 
The severity of the adverse reaction is unknown 
or not stated. 
Definite: 
Conclusive evidence exists that the 
adverse reaction can be attributed to 
the transfusion. 
 
 
Probable: 
Evidence is clearly in favor of 
attributing the adverse reaction to 
the transfusion. 
 
 
Possible: 
Evidence is indeterminate for 
attributing the adverse reaction to 
the transfusion or an alternate 
cause. 
 
 
Doubtful: 
Evidence is clearly in favor of a 
cause other than the transfusion, but 
transfusion cannot be excluded. 
 
 
Ruled Out: 
There is conclusive evidence 
beyond reasonable doubt of a cause 
other than the transfusion. 
 
 
Not Determined: 
The relationship between the 
adverse reaction and the transfusion 
is unknown or not stated. 
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Adverse Reaction Glossary 
 
 
Antibodies often associated with AHTR, DHTR, DSTR: 
Anti-A Anti-B Anti-A,B Anti-C Anti-c Anti-D Anti-E Anti-e Anti-Fya 
Anti-Fyb Anti-Jka Anti-Jkb Anti-K Anti-k Anti-M Anti-S Other  
 
Bronchospasm (wheezing):  A contraction of smooth muscle in the walls of the bronchi and 
bronchioles, causing acute narrowing and obstruction of the respiratory airway. This constriction can 
result in a rasp or whistling sound while breathing. 
 
Chills/rigors:  A feeling of cold with shivering or shaking and pallor. 
 
Disseminated intravascular coagulation (DIC):  Bleeding disorder characterized by reduction in the 
factors involved in blood clotting due to their use in widespread clotting within the vessels. The 
intravascular clotting ultimately produces hemorrhage because of rapid consumption of clotting factors. 
 
Edema:  Swelling of soft tissues as a result of excessive fluid accumulation. 
 
Epistaxis:  Bleeding from the nose. 
 
Fever: For the purposes of hemovigilance, an increase of at least 1°C in temperature over the pre-
transfusion value. 
 
Hematuria:  Presence of blood or red blood cells in the urine. 
 
Hemoglobinemia:  The presence of free hemoglobin in the blood plasma. 
 
Hemoglobinuria:  Presence of free hemoglobin in the urine. 
 
Hypoxemia:  Abnormal deficiency in the concentration of oxygen in arterial blood. PaO2 / FiO2 less 
than or equal to 300 mm Hg OR oxygen saturation is less than 90% on room air. 
 
Jaundice:  New onset or worsening of yellow discoloration (icterus) of the skin or sclera (scleral icterus) 
secondary to an increased level of bilirubin.  
 
Oliguria:  New onset of decreased urinary output (less than 500cc output per 24 hours). 
 
Other rash:  Non-urticarial skin rash. 
 
Pruritus:  Itching. 
 
Shock:  A drop in blood pressure accompanied by a drop in cardiac output including rapid heart rate 
(increase to 100 beats per minute or more), rapid breathing, cutaneous vasoconstriction, pallor, 
sweating, decreased or scanty urine production, agitation and/or loss of consciousness that required 
fluid resuscitation, with or without inotropic support.  
 
Shortness of breath (dyspnea):  New onset or significant worsening of shortness of breath; or a 
significant increase in respiratory rate (with or without hypoxemia). 
 
Urticaria (hives):  Raised wheals on the skin. 
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Section 4. Hemovigilance Module Incidents 
 
 
Required Reporting 
All incidents (i.e., accidents or errors) that are associated with a reported adverse reaction must be 
reported to NHSN using a detailed Incident form (CDC 57.305). If multiple incidents occur in association 
with an adverse reaction then report all. Incidents may occur before (e.g., wrong product released) or 
after (e.g., failure to report adverse reaction to blood bank) an adverse reaction. Each reaction must be 
reported using the detailed incident form; the incident result must be coded as ‘Product transfused, 
reaction’ to enter the associated patient identifier on the form. After the incident record is entered, the 
adverse reaction record must be linked to the incident record in the NHSN web application. 
 
 
Incident Classification 
Use the incident codes provided at the end of this section to classify incidents. If there is uncertainty then 
please contact NHSN User Support 
 
 
Optional Reporting 
Any incident may be optionally reported to NHSN using the detailed Incident form (57.305) or the 
Monthly Incident Summary form (57.302). Approved deviations from standard operating procedure are 
not considered incidents because they did not occur by accident or in error. However, approved 
deviations may be optionally reported for a facility’s use. Incidents that are optionally reported will not be 
aggregated or analyzed by CDC. 
 
 
Form 
CDC 57.305 Hemovigilance Module Incident 
 
Form Instructions 
CDC 57.305 Hemovigilance Module Incident Table of Instructions 
 
Summary Form (Optional) 
CDC 57.302 Hemovigilance Module Monthly Incident Summary 
 
Summary Form Instructions (Optional) 
CDC 57.302 Hemovigilance Module Monthly Incident Summary Table of Instructions 
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Incident Codes 
Note:  Incident codes are based on MERS TM (US) and TESS (Canada) incident classification schemes. 
 
Product Check-In 
(Transfusion Service) 
Events that occur during the shipment and receipt of 
products into the transfusion service from the 
supplier, another hospital site, satellite storage, or 
clinical area. 
PC 00 Detail not specified 
PC 01 Data entry incomplete/incorrect/not performed 
PC 02 Shipment incomplete/incorrect 
PC 03 Products and paperwork do not match 
PC 04 Shipped/transported under inappropriate 
conditions 
PC 05 Inappropriate return to inventory 
PC 06 Product confirmation incorrect/not performed 
PC 07 Administrative check not incorrect/not 
performed (record review/audit) 
PC 08 Product label incorrect/missing 
 
Product Storage 
(Transfusion Service) 
Events that occur during product storage by the 
transfusion service. 
US 00 Detail not specified 
US 01 Incorrect storage conditions 
US 03 Inappropriate monitoring of storage device 
US 04 Unit stored on incorrect shelf (e.g., 
ABO/autologous s/directed) 
US 05 Incorrect storage location 
 
Inventory Management 
(Transfusion Service) 
Events that involve quality management of the blood 
product inventory. 
IM 00 Detail not specified 
IM 01 Inventory audit incorrect/not performed 
IM 02 Product status incorrectly/not updated online 
(e.g., available/discarded) 
IM 03 Supplier recall/traceback not appropriately 
addressed/not performed 
IM 04 Product order incorrectly/not submitted to 
supplier 
IM 05 Outdated product in available inventory 
IM 06 Recalled/quarantined product in available 
inventory 
 
 
 
Product/Test Request 
(Clinical Service) 
Events that occur when the clinical service orders 
patient tests or blood products for transfusion. 
PR 00 Detail not specified 
PR 01 Order for wrong patient 
PR 02 Order incompletely/incorrectly ordered (online 
order entry) 
PR 03 Special processing needs not indicated (e.g., 
CMV negative, autologous) 
PR 04 Order not done 
PR 05 Inappropriate/unnecessary (intended) test 
ordered 
PR 06 Inappropriate/unnecessary (intended) blood 
product ordered 
PR 07 Incorrect (unintended) test ordered 
PR 08 Incorrect (unintended) blood product ordered 
 
Product/Test Order Entry 
(Transfusion Service) 
Events that occur when the transfusion service 
receives a patient order. This process may be 
excluded if clinical service uses online ordering. 
OE 00 Detail not specified 
OE 01 Order entered for wrong patient 
OE 02 Order incompletely/incorrectly entered online 
OE 03 Special processing needs not entered (e.g., 
CMV-, autologous) 
OE 04 Order entry not done 
OE 05 Inappropriate/unnecessary (intended) test 
order entered 
OE 06 Inappropriate/unnecessary (intended) blood 
product order entered 
OE 07 Incorrect (unintended) test ordered 
OE 08 Incorrect (unintended) blood product ordered 
 
Sample Collection 
(Service collecting the samples) 
Events that occur during patient sample collection. 
SC 00 Detail not specified 
SC 01 Sample labeled with incorrect patient name 
SC 02 Not labeled 
SC 03 Wrong patient collected 
SC 04 Collected in wrong tube type 
SC 05 Sample QNS 
SC 06 Sample hemolyzed 
SC 07 Label incomplete/illegible/incorrect (other than 
patient name) 
SC 08 Sample collected in error 
SC 09 Requisition arrived without samples 
SC 10 Wristband incorrect/not available 
SC 11 Sample contaminated 
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Incident Codes  
(continued) 
Note:  Incident codes are based on MERS TM (US) and TESS (Canada) incident classification schemes. 
 
Sample Handling 
(Service collecting the samples) 
Events that occur when a patient sample is sent for 
testing. 
SH 00 Detail not specified 
SH 01 Sample sent without requisition 
SH 02 Requisition and sample label don’t match 
SH 03 Patient ID incomplete/illegible on requisition 
SH 04 No Patient ID on requisition 
SH 05 No phlebotomist/witness identification 
SH 06 Sample sent with incorrect requisition type 
SH 07 Patient information (other than ID) 
missing/incorrect on requisition 
SH 08 Requisition sent without sample 
SH 09 Data entry incorrect/incomplete/not performed 
SH 10 Sample transport issue (e.g., sample 
broken/inappropriate conditions) 
SH 11 Duplicate sample sent in error 
 
Sample Receipt 
(Transfusion Service) 
Events that occur when a sample is received by the 
transfusion service. 
SR 00 Detail not specified 
SR 01 Sample accepted in error 
SR 02 Historical review incorrect/not performed 
SR 03 Demographic review/ data entry incorrect/not 
performed 
SR 04 Sample incorrectly accessioned 
 
Sample Testing 
(Transfusion Service) 
Events that occur during patient sample testing by 
the transfusion service. 
ST 00 Detail not specified 
ST 01 Data entry incomplete/incorrect/not performed 
ST 02 Appropriate sample checks 
incomplete/incorrect/not performed 
ST 03 Computer warning overridden in error or 
outside SOP 
ST 05 Sample test tube incorrectly accessioned 
ST 07 Sample test tubes mixed up 
ST 09 Sample test tube mislabeled (wrong patient 
identifiers) 
ST 10 Equipment problem/failure/not properly QC’d 
ST 12 Sample testing not performed 
ST 13 Incorrect sample testing method chosen 
ST 14 Sample testing performed incorrectly 
ST 15 Sample test result misinterpreted 
 
Sample Testing (continued) 
ST 16 Reagents used were 
incorrect/inappropriate/expired/not properly 
QC’d 
ST 17 ABO/Rh error caught on final check 
ST 18 Current/historical ABO/Rh mismatch  
ST 19 Additional testing not performed 
ST 20 Confirmatory check incorrect/not performed (at 
time work performed) 
ST 21 Administrative check incorrect/not performed 
(record review/audit) 
ST 22 Sample storage incorrect/inappropriate 
 
Product Manipulation/Processing/Testing 
(Transfusion Service) 
Events that occur while testing, manipulating (e.g., 
pooling, washing, aliquoting, irradiating), processing, 
or labeling blood products. 
UM 00 Detail not specified 
UM 01 Data entry incomplete/incorrect/not performed 
UM 02 Record review incomplete/incorrect/not 
performed 
UM 03 Incorrect product (type) selected  
UM 04 Incorrect product (patient) selected 
UM 05 Product labeled incorrectly (new/updated) 
UM 06 Computer warning overridden in error or 
outside SOP 
UM 07 Special processing needs not checked 
UM 08 Special processing needs misunderstood or 
misinterpreted 
UM 09 Special processing needs performed 
incorrectly  
UM 10 Special processing needs not performed 
UM 11 Equipment problem/failure/not properly QC’d 
UM 12 Reagents used were 
incorrect/inappropriate/expired/not properly 
QC’d 
UM 13 Confirmatory check incorrect/not performed (at 
time work performed) 
UM 14 Administrative check incorrect/not performed 
(record review/audit) 
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Incident Codes  
(continued) 
Note:  Incident codes are based on MERS TM (US) and TESS (Canada) incident classification schemes. 
 
Request for Pick-up 
(Clinical Service) 
Events that occur when the clinical service requests 
pick-up of a blood product from the transfusion 
service. 
RP 00 Detail not specified 
RP 01 Request for pick-up on wrong patient 
RP 02 Incorrect product requested for pick-up 
RP 03 Product requested prior to obtaining consent 
RP 04 Product requested for pick-up, but patient not 
available 
RP 05 Product requested for pick-up, but IV not ready 
RP 06 Request for pick-up incomplete (e.g., patient 
ID/product type missing) 
RP 07 Pick-up slip did not match patient information 
on product 
 
Product Issue 
(Transfusion Service) 
Events that occur when the transfusion service 
issues blood product to the clinical service.  
UI 00 Detail not specified 
UI 01 Data entry incomplete/incorrect/not performed 
UI 02 Record review incomplete/incorrect/not 
performed 
UI 03 Product issued for wrong patient  
UI 04 Product issued out of order 
UI 05 Product issue delayed 
UI 06 LIS warning overridden in error or outside SOP 
UI 07 Computer issue not completed 
UI 08 Issued visibly defective product (e.g., 
clots/aggregates/particulate matter) 
UI 09 Not/incorrect checking of unit and/or patient 
information 
UI 10 Product transport issues (e.g., delayed) by 
transfusion service 
UI 11 Unit delivered to incorrect location by 
transfusion service 
UI 12 Product transport issue (from transfusion 
service to clinical area) 
UI 18 Wrong product issued for intended patient (e.g., 
incompatible) 
UI 19 Inappropriate product issued for patient (e.g., 
not irradiated, CMV+) 
UI 20 Confirmatory check incorrect/not performed (at 
time work performed) 
UI 21 Administrative check incorrect/not performed 
(record review/audit) 
UI 22 Issue approval not obtained/documented 
UI 23 Receipt verification not performed (pneumatic 
tube issue) 
 
 
Satellite Storage 
(Clinical Service) 
Events that occur while product is stored and 
handled by the clinical service. 
CS 00 Detail not specified 
CS 01 Incorrect storage conditions of product in 
clinical area 
CS 02 Incorrect storage location in the clinical area 
CS 03 Labeling issue (by clinical staff) 
CS 04 Floor/clinic did not check for existing products 
in their area 
CS 05 Product transport issues (to or between clinical 
areas) 
CS 06 Monitoring of satellite storage 
incorrect/incomplete/not performed 
CS 07 Storage tracking/documentation 
incorrect/incomplete/not performed 
 
Product Administration 
(Clinical Service) 
Events that occur during the administration of blood 
products. 
UT 00 Detail not specified 
UT 01 Administered intended product to wrong patient 
UT 02 Administered wrong product to intended patient 
UT 03 Transfusion not performed in error 
UT 05 Bedside check (patient ID confirmation) 
incomplete/not performed 
UT 06 Transfused product with incompatible IV fluid 
UT 07 Transfusion delayed beyond pre-approved 
timeframe 
UT 09 Transfused unsuitable product (e.g., 
outdated/inappropriately stored) 
UT 10 Administered components in wrong order 
UT 11 Appropriate monitoring of patient not 
performed 
UT 14 Transfusion volume too low (per order or SOP) 
UT 15 Transfusion volume too high (per order or 
SOP) 
UT 16 Transfusion rate too slow (per order or SOP) 
UT 17 Transfusion rate too fast (per order or SOP) 
UT 18 Inappropriate preparation of product 
UT 19 Transfusion protocol not followed (not 
otherwise specified) 
UT 22 Order/consent check incorrect/not performed  
UT 23 Transfusion documentation 
incorrect/incomplete/not performed 
UT 24 Transfusion documentation not returned to 
transfusion service 
UT 26 Transfusion reaction protocol not followed 
 
Other  
MS 99 Other 
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Occupation Codes 
 
Laboratory Additional Occupation Types 
IVT IVT Team Staff ATT Attendant/Orderly 
MLT Medical Laboratory Technician CSS Central Supply 
MTE Medical Technologist CSW Counselor/Social Worker 
PHL Phlebotomist/IV Team DIT Dietician  
Nursing DNA Dental Assistant/Technician 
LPN Licensed Practical Nurse DNH Dental Hygienist 
CNA Nurse Anesthetist DNO Other Dental Worker 
CNM Certified Nurse Midwife  DNT Dentist 
NUA Nursing Assistant DST Dental Student 
NUP Nurse Practitioner FOS Food Service 
RNU Registered Nurse HSK Housekeeper 
Physician ICP Infection Control Professional 
FEL Fellow LAU Laundry Staff 
MST Medical Student MNT Maintenance/Engineering 
PHY Attending/Staff Physician MOR Morgue Technician 
RES Intern/Resident  OAS Other Ancillary Staff 
Technicians OFR Other First Responder 
EMT EMT/Paramedic OH Occupational Health Professional 
HEM Hemodialysis Technician OMS Other Medical Staff 
ORS OR/Surgery Technician OTH Other 
PCT Patient Care Technician OTT Other Technician/Therapist 
Other Personnel PAS Physician Assistant 
CLA Clerical/Administrative PHA Pharmacist 
TRA Transport/Messenger/Porter PHW Public Health Worker 
  PLT Physical Therapist 
  PSY Psychiatric Technician 
  RCH Researcher 
  RDT Radiologic Technologist 
  RTT Respiratory Therapist/Technician 
  STU Other Student 
  VOL Volunteer 
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Incident Glossary 
 
Incident Result 
Product transfused; reaction (No recovery; harm): 
A product related to this incident was transfused; the patient experienced an adverse reaction. 
 
Product transfused; no reaction (No recovery; no harm): 
A product related to this incident was transfused; the patient did not experience an adverse reaction. 
 
No product transfused; unplanned recovery (Near miss; unplanned recovery): 
No product related to this incident was transfused; the incident was discovered ad hoc, by accident, by 
human lucky catch, etc. 
 
No product transfused; planned recovery (Near miss; planned recovery): 
No product related to this incident was transfused; the incident was discovered through a standardized 
process or barrier designed to prevent errors. 
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Section 5. Hemovigilance Module Denominators 
 
 
Required Reporting 
Facilities must report the total number of units and aliquots of specified blood components transfused 
and total number of discards each month. When reporting aliquots, the units from which they are made 
should NOT be counted as a transfused unit. The components transfused count should include 
autologous units. The total number of patient samples collected and total crossmatch procedures must 
also be reported. This form must be completed each month that surveillance is conducted and data can 
only be entered once the calendar month is over. For instance, February data must be entered after 
March 1st. Additionally, data cannot be entered for upcoming months. 
 
Pathogen Reduced Blood Products 
The total number of transfused units of blood components which are produced with pathogen-reduction 
technology (PRT) should be reported each month, if applicable. These PRT units are reported in Table 2 
and are a subset of total number of units and aliquots transfused that are reported in Table 1. Table 3 
relates to pathogen reduced apheresis platelets, if reported in table 2. For more guidance please refer to 
the Denominator QuickLearn on the NHSN Blood Safety Surveillance website.  
 
 
 
Electronic Reporting 
In January 2017, the NHSN Hemovigilance module can accept electronically reported denominator data 
via clinical documentation architecture (CDA). Compared to manual reporting, electronic reporting will 
decrease the time required for data collection and reporting, reduce data entry errors, and increase data 
granularity. In order to electronically report date, facilities’ software system must have CDA functionality.  
For more information about electronic reporting and CDA, review CDA Frequently Asked Questions 
guidance on the NHSN Blood Safety Surveillance website.   
 
 
 
Form 
CDC 57.303 Hemovigilance Module Monthly Reporting Denominators 
 
Form Instructions 
CDC 57.303 Hemovigilance Module Monthly Reporting Denominators Tables of Instructions 
 
 
